key: cord-1010433-7vh7d3p4
authors: Abdelgalil, Abobakr A.; Saeedi, Fajr A
title: Multisystem Inflammatory Syndrome in a 12-Year-old Boy After mRNA-SARS-CoV-2 Vaccination
date: 2021-12-21
journal: Pediatr Infect Dis J
DOI: 10.1097/inf.0000000000003442
sha: cc90a56e311430d9be1a8beb273c76625fa61aa6
doc_id: 1010433
cord_uid: 7vh7d3p4

Multisystem inflammatory syndrome in children (MIS-C) following SARS-CoV-2 infection is well known. We describe a 12-year-old child developing MIS-C after receiving 2 doses of mRNA COVID-19 vaccines without clinical evidence of COVID-19 infection. A possible association between the SARS-CoV-2 vaccine and MIS-C cannot be excluded.

M ultisystem inflammatory syndrome in children (MIS-C) following SARS-CoV-2 infection is relatively well known. 1 A similar multisystem hyper-inflammatory syndrome following COVID-19 vaccination is not well described in the pediatric age group. We describe a 12-year-old child developing MIS-C after receiving 2 doses of mRNA COVID-19 vaccines. A possible association between the SARS-CoV-2 vaccine and MIS-C cannot be excluded.

A 12-year-old boy presented by continuous, high-grade fever for 3 days, redness of eyes, followed by a diffuse erythematous nonitchy rash, fatigue and abdominal pain, 5 weeks after his second dose of Moderna vaccine that was preceded by the first dose of Pfizer-BioNTech vaccine given 3 weeks apart. He had no history of COVID-19 infection or exposure. He had no history of cough or respiratory symptoms, headache, seizures or joint pain. There was also no history of recent travel, contact with sick persons, bird or animal exposure and no raw milk product use. There were no known allergies or drug use. On admission, he was hypotensive and febrile, with mild tachypnea and tachycardia. There was bilateral conjunctivitis but no lymphadenopathy or sore throat. Cardiac, chest, abdominal and neurologic examination was unremarkable. Two days later, the patient developed vomiting, diarrhea and facial puffiness.

SARS-CoV-2 PCR was negative, but SARS-CoV-2 IgG (against S protein) was highly positive (>5680 IU/ML). He had increased inflammatory markers and troponin level, and also, he had thrombocytopenia, neutrophilia and lymphopenia. Echocardiography showed mildly affected LV function (EF=55%). Investigations are illustrated in Table 1 .

The diagnosis of MIS-V, or MIS-C following vaccination was entertained. In addition to intravenous fluids, acetaminophen and empirical antibiotic use (azithromycin and ceftriaxone), we started intravenous immunoglobulin 2 gm/kg on the fourth day of admission. He responded well, with resolution of fever, rash and facial swelling and also his laboratory parameters started to improve. The patient developed thrombocytosis so the patient was discharged on aspirin 81 mg/d to be followed in the clinic one week after discharge. He returned to his premorbid baseline except mild fatigue.

There are few reports of MIS-C following SARS-CoV-2 vaccination and almost all reported cases have been diagnosed in 

Multisystem inflammatory syndrome in an adult following the SARS-CoV-2 vaccine (MIS-V)

Multisystem inflammatory syndrome after SARS-CoV-2 infection and COVID-19 vaccination

Multisystem inflammatory syndrome in a male adolescent after his second Pfizer-BioNTech COVID-19 vaccine

Fatal multisystem inflammatory syndrome in adult after SARS-CoV-2 natural infection and COVID-19 vaccination

Multisystem inflammatory syndrome in children and adults (MIS-C/A): case definition & guidelines for data collection, analysis, and presentation of immunization safety data